Clinical trials: Clostridium Infections
Pertussis, Whooping Cough
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
This study will evaluate the safety and efficacy of 9 different vaccines containing aP (acellular pertussis) and TdaP (acellular pertussis, tetanus and diphtheria) in healthy subjects 18 to 40 years of age.
- Conditions
- Pertussis, Whooping Cough, Tetanus, Lockjaw
- Trial name
- NCT01529645
- Testing
- Acellular pertussis vaccine, Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed), Licensed TdaP booster vaccine
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B, Diphtheria
A Phase IV Study to Assess the Safety of EupentaTM Inj
A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj.{fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic…
- Conditions
- Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection, Tetanus
- Trial name
- NCT04056728
- Testing
- Eupenta Inj.
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Chem
Pertussis, Diphtheria
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
To compare the reactogenicity of ADACEL® vaccine given at intervals of 2 to 9 years with the reactogenicity of ADACEL® vaccine given at an interval of 10 or more years following the last previous administration of vaccine…
- Trial name
- NCT00524732
- Testing
- Tetanus and diphtheria toxoids and acellular pertussis
- Where
- 2 sites in Canada
- Volunteers
- 7,156 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
The purpose of this study is to determine whether Fecal Microbiota Therapy (FMT) is effective vs. placebo in the prevention of C. difficile infection recurrence.
- Trial name
- MATCH (NCT03005379)
- Testing
- Fecal Microbiota Therapy (FMT)
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Clostridium Difficile, Clostridium Difficile Infection
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, Microbiome, CDI
- Trial name
- NCT04100603
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Tetanus
Tdap Vaccine Safety for Plasma Donors
This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations)…
- Trial name
- NCT04142983
- Testing
- Adacel
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GCAM Inc.
Tetanus
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of…
- Trial name
- NCT06120751
- Testing
- TTVA, TT
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age…
- Trial name
- NCT05169905
- Testing
- RSV MAT vaccine, dTpa vaccine
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Clostridium Difficile Infection
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01914731
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clostridium Difficile Infection
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Clostridium difficile associated diarrhoea is an important cause of morbidity in patients treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of initially successful treatments for colitis.
- Trial name
- RAPID (NCT01670149)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 151 people
- Sponsor
- University of Nottingham
Intestinal Infection, Clostridioides Difficile Infection
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
A national data registry of patients receiving the rescue fecal microbiota transplantation for the refractory intestinal infections from the China Microbiota Transplantation System was designed to assess the short-term and…
- Conditions
- Intestinal Infection, Clostridioides Difficile Infection, Antibiotic-associated Diarrhea
- Trial name
- NCT03895593
- Testing
- rescue fecal microbiota transplantation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Haemophilus Influenzae Type b, Tetanus
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
The purpose of the study is as follows: To evaluate the persistence of antibodies and the presence of immune memory induced by a 3-dose primary vaccination with Tritanrix™-HepB/Hib-MenAC (three formulations) in the study…
- Conditions
- Haemophilus Influenzae Type b, Tetanus, Whole Cell Pertussis, Hepatitis B
- Trial name
- NCT00317174
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- Philippines
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine
An open clinical trial to study the immune response and safety after giving a booster dose (5th Dose) of a combination vaccine against Diphteria-Tetanus-Pertussis-Polio to healthy adolescents 15-16 Years of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00514059
- Testing
- Boostrix polio
- Where
- Norway
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
Botulism, Iatrogenic Botulism
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
- Trial name
- NCT05769478
- Testing
- Amifampridine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
C. Diff. Infections
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.
- Trial name
- NCT04893239
- Testing
- LMN-201 Anti-toxin B VHH-1, LMN-201 Anti-toxin B VHH-2, LMN-201 Anti-toxin B VHH-3
- Where
- 3 sites in Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Clostridium Difficile Infection
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01704937
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Diphtheria, Tetanus
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
The purpose of this study is to evaluate safety and immunogenicity of Pediacel® in infants and toddlers when given at 2,3,4 and 12-18 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00343421
- Testing
- PEDIACEL® and Prevenar®, Infanrix®-IPV+Hib and Prevenar®
- Where
- 2 sites in France, Poland
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
This is a Phase I, single center, randomized, placebo-controlled, double-blind, multiple ascending dose study to evaluate the safety and tolerability of CRS3123, a methionyl-tRNA synthetase inhibitor.
- Trial name
- NCT02106338
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)